Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Telmisartan/Amlodipine/HCTZ FDC vs Co-administration in Healthy Males
NCT02121535Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2014
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of telmisartan + amlodipine + hydrochlorothiazide in hypertension (HTN) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of Telmisartan in Plasma from 0 to Last Quantifiable Data Point, Maximum Plasma Concentration for Telmisartan and 4 more. Started Apr 2014; status: completed.
02
Drugs
telmisartan + amlodipine + hydrochlorothiazide
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02121535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02121535.